Bluejay Diagnostics (NASDAQ:BJDX) Shares Up 12.7%

Shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDXGet Free Report) traded up 12.7% during mid-day trading on Monday . The stock traded as high as $0.65 and last traded at $0.62. 41,154 shares were traded during trading, a decline of 12% from the average session volume of 46,850 shares. The stock had previously closed at $0.55.

Bluejay Diagnostics Stock Down 12.0 %

The business has a fifty day moving average price of $0.75 and a 200-day moving average price of $1.88. The company has a market cap of $1.48 million, a P/E ratio of -0.06 and a beta of 0.85.

Bluejay Diagnostics (NASDAQ:BJDXGet Free Report) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($1.10).

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDXFree Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned 1.95% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. 18.47% of the stock is owned by institutional investors and hedge funds.

Bluejay Diagnostics Company Profile

(Get Free Report)

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.

Featured Articles

Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with's FREE daily email newsletter.